Navigation Links
Tumor Growth Inhibition and Pharmacokinetic Profile of NKTR-102 (PEG-Irinotecan) in Multiple Solid Tumors To Be Presented at Upcoming AACR-NCI-EORTC International Conference
Date:10/10/2007

SAN CARLOS, Calif., Oct. 10 /PRNewswire-FirstCall/ -- Nektar Therapeutics (Nasdaq: NKTR) announced today that preclinical data for its proprietary product candidate NKTR-102 (PEG-irinotecan) will be presented at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Therapeutics in San Francisco, California on October 25, 2007. The presentations will highlight new results from preclinical trials of NKTR-102 in mouse models of colorectal, lung and breast cancers. NKTR-102 is a PEGylated form of irinotecan created using Nektar's innovative small molecule PEGylation technology platform and is in Phase 1 clinical development for the treatment of solid tumors.

In preclinical studies presented at ECCO 14 in September, NKTR-102 substantially suppressed tumor growth in an irinotecan-resistant mouse colorectal tumor model, while irinotecan-treated groups did not show a statistically significant decrease in tumor growth compared to controls. Further, administration of NKTR-102 resulted in a significantly improved pharmacokinetic profile for the active metabolite of irinotecan as compared to treatment with irinotecan.

"The studies for NKTR-102 continue to indicate that Nektar's small molecule PEGylation technology can be a powerful platform for improving chemotherapeutic agents," Tim Riley, Ph.D., Vice President of PEGylation Research at Nektar. "The new preclinical data in colorectal, lung and breast tumor models also highlights the promise of NKTR-102 to serve as a potentially new and powerful therapy in multiple solid tumor settings."

Two poster presentations are scheduled:

October 25, 2007 - 12:30 PM - 2:00 PM (PT); 5:30 - 7:30 PM (PT)

Poster Session C -- AACR-NCI-EORTC
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
2. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
3. Prolexys Pharmaceuticals and Columbia University Researchers Publish Study on Anti-Tumor Properties of a Selective Small Molecule Anti-Tumor Agent With Novel Mechanism of Action
4. NCI Researchers Discover Genes That Are Turned on at High Levels in Tumor-associated Blood Vessels of Mice and Humans
5. Clinical Data Reported on Vidaza in Hematologic Malignancies and Advanced Solid Tumors
6. Introgen Reports Updated Phase 2 Advexin Data Correlating Improved Survival, Tumor Responses and Predictive p53 Biomarker
7. Merck at ASCO 2007: Encouraging Results in Progression-Free Survival in Patients With Aggressive Brain Tumors (glioblastoma) Using Cilengitide in Phase I/IIa Study
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
10. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
11. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Most osteoporosis patients want a choice in the medication ... by Mission Pharmacal Company. The survey, conducted by ... community, revealed that 74 percent of osteoporosis patients surveyed ... other than a pill or a tablet. ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... received commitments from institutional investors to purchase an aggregate ... in an at-the-market registered direct offering, led by a ... into definitive purchase agreements with these investors pursuant to ...
(Date:1/15/2014)... 2014  Manufacturers, suppliers and distributors of innovative medical-related ... their most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the ... the most litigious industry sectors of cases involving ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... on study results demonstrating survival advantage ... months when added to standard therapy, -- First study ... BOULDER, Colo., Jan. 24 Pharmion Corporation,(Nasdaq: PHRM ) ... positive opinion to recommend approval of Thalidomide,Pharmion(R) for use in ...
... with Fractionated Lasers Or in ... the Eyes, WALTHAM, Mass., Jan. 24 When it ... no longer the only option. According to the,American Academy of ... who is interested in non-surgical options to obtain the,best results. ...
Cached Medicine Technology:Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 2Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 3Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 4Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 5Thalidomide Pharmion(R) Receives Positive Opinion for Treatment of First-line Multiple Myeloma from European Medicines Agency 6Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 2Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 3Portrait(R) Plasma - A New Non-Surgical Option for one of the Most Requested Aesthetic Treatment - Aging Eyes 4
(Date:7/9/2014)... Researchers have found that fecal transplantation is effective ... immunocompromised patients. This is the result of a study ... Center for Women,s Gastrointestinal Medicine at The Women,s Medicine ... online in advance of print in the American ... or C. diff , has increased to epidemic ...
(Date:7/9/2014)... news release is available in French . ... factors in 14 year old teens, including brain structure and ... 70% accuracy who will go on to develop binge drinking ... of conscientiousness, and other variables such as life events and ... of binge drinking. Whether or not the child had ...
(Date:7/9/2014)... is for more than watching World Cup highlights, Brian ... skateboarders landing in unfortunate positions on railings. A University ... Dermatology Online Journal shows that YouTube also allows ... the public on topics of skin cancer and prevention. ... is the future of how we communicate around the ...
(Date:7/9/2014)... 9, 2014) A retrospective study conducted by researchers ... reports that among adults with intellectual and developmental disabilities, ... of years receiving dental care increased. The findings, published ... Dentistry , may help improve interventions designed to address ... , The researchers reviewed the dental records of 107 ...
(Date:7/9/2014)... 9, 2014 A study published in the scientific ... and Robert Bonin, two researchers at Universit Laval, reveals ... a new method that involves rekindling pain so that ... to novel means to alleviate chronic pain. , The ... and Institut universitaire en sant mentale de Qubec (IUSMQ) ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:What drives a child to abuse alcohol? 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2Health News:Adults with special needs see gains, challenges with long term oral care 2Health News:Adults with special needs see gains, challenges with long term oral care 3Health News:Discovery of a new means to erase pain 2
... productivity industry, WASHINGTON, March 31 The ... on Health (NBCH), two,nationally-recognized non-profit organizations focused on ... and quality of life, are,partnering to host the ... will take place February 9-11, 2009 at the ...
... of elderly patients could cut their total mortality by ... a third, according to a new study presented today ... in Chicago and published simultaneously in the New England ... the Very Elderly Trial (HYVET), which is coordinated by ...
... Chicago, IL, March 31, 2008 New data ... technology found that in patients living with type ... burden in the coronary arteries compared to glimepiride, ... data stem from the PERISCOPE (Pioglitazone Effect on ...
... DIEGO, March 31 Amira Pharmaceuticals, a small,molecule ... of,compounds to treat inflammatory disease, today announced the ... directors: Dennis M. Fenton, Ph.D.,and Stephen W. Kaldor, ... pharmaceutical and biotechnology experience,including over two decades at ...
... Focus on Delivering on ... 2008 Free Cash Flow Target, SIOUX ... the leading provider of media and,connectivity solutions to hospitality and healthcare ... Conference at The Palms,Hotel in Las Vegas on Wednesday, April 2. ...
... 31 Greenway Medical Technologies,announced today its expanded ... Quality Reporting Initiative (PQRI) and Pay for,Performance (P4P) ... technology (HIT) adoption., The PQRI, which was ... Medicare, Medicaid, and SCHIP Extension Act of 2007, ...
Cached Medicine News:Health News:Integrated Benefits Institute and National Business Coalition on Health to Host First Annual Health and Productivity Forum 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 2Health News:Significant reductions in mortality shown using blood pressure-lowering treatment in very elderly 3Health News:New data showed Actos prevented progression of atherosclerotic plaque volume in patients 2Health News:Dr. Dennis Fenton and Dr. Steve Kaldor Join Amira Board of Directors 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 2Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 3Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 4Health News:LodgeNet Interactive to Present at The B. Riley Investor Conference 5Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 2Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 3Health News:Greenway Medical Technologies Expands Support for Physician Quality Reporting Initiative and Pay for Performance Programs 4
Portex® Blue Line® cuffed endotracheal tubes come in a wide selection of sizes, each with a standard 15 mm ISO connector., ,Portex® Blue Line® endotracheal tubes are recognized world...
... PVC. 2 eyes, oral. Marked with ... X-ray opaque line. Graduated. Single use. ... reduce kinking of the tube by ... adapts to the anatomical situation at ...
... Ruschelit® PVC. Murphy eye-oral. High volume/low ... Oral Cuffed Single use. For improved ... of the tube by incorporating a ... cuff. Thermosensitive Ruschelit® PVC adapts to ...
Ruschelit® PVC. Siliconized. Stainless steel spiral reinforced. Murphy eye. High volume/low pressure cuff. Connector is permanently fixed into the tube. X-ray opaque. Graduated. Single use. Steri...
Medicine Products: